BioNTech (BNTX) Stock Plunges 20% After Earnings Miss and Leadership Change

BioNTech SE (NASDAQ: BNTX) shares cratered more than 20% on Tuesday, March 10, 2026, following a double blow to investor confidence: a Q4 2025 earnings miss and a bombshell announcement that both of the company’s iconic co-founders plan to exit by the end of 2026. The stock, which closed at $102.16 the prior session, plummeted to around $80.46 in intraday trading, hitting a fresh 52-week low, as markets digested weak forward guidance and the looming leadership vacuum at one of the world’s most prominent biotechnology firms.

Earnings Miss and Weak 2026 Guidance Shake Investor Confidence

BioNTech reported Q4 2025 revenue of €907.4 million, surpassing the analyst estimate of $758.8 million, but the earnings picture was far less encouraging. The company posted an adjusted loss of -$0.33 per share, significantly worse than the consensus estimate of -$0.19, as the post-pandemic COVID-19 vaccine revenue tailwind continues to fade. The Q4 figure represented a steep 24% year-over-year decline from €1.19 billion in Q4 2024, driven primarily by reduced demand for the Comirnaty vaccine developed with Pfizer.

For the full year 2025, BioNTech managed €2.9 billion in revenues, a modest 4% increase, but swung to an adjusted net loss of €117.1 million compared to a profit of €121.7 million the prior year. Most damaging to the stock was 2026 revenue guidance of €2.0–€2.3 billion, with a midpoint roughly 25% below the FactSet consensus of €2.75 billion. Combined with projected R&D expenses of €2.2–€2.5 billion, the spending trajectory against shrinking vaccine revenues raised serious near-term profitability concerns that investors were quick to price in.

Join our Telegram group and never miss a breaking digital asset story.

Co-Founder Departures Add Leadership Uncertainty

BioNTech also revealed that its board has initiated a formal executive search to replace CEO Ugur Sahin and Chief Medical Officer Özlem Türeci — the husband-and-wife duo who co-founded the company and guided it from a German oncology startup to a global mRNA powerhouse.

Both are expected to transition out by the end of 2026 to lead a newly formed company focused on next-generation mRNA innovations, a disclosure that deepened the market selloff beyond what the earnings miss alone might have caused.

Sahin and Türeci are the scientific and strategic architects of BioNTech’s oncology pipeline, spanning candidates including BNT111 for melanoma, BNT113 for head and neck cancer, and BNT116 for non-small cell lung cancer. Their departure introduces meaningful uncertainty around the company’s long-term research direction at a critical period of pipeline maturation.

That said, BioNTech’s balance sheet remains a strong counterargument to outright pessimism, the company ended 2025 with €17.2 billion in cash, and the analyst consensus price target of $137.67 suggests significant upside from current levels for those willing to look past the near-term turbulence.

BNTX Stock Snapshot: Key Metrics as of March 10, 2026

As of approximately 10:22 AM EDT, BNTX was trading at $80.46, down $21.70 or -21.24% on the session, having opened at $82.81 against a prior close of $102.16. The stock touched an intraday low of $79.52, its new 52-week low, on volume exceeding 4.77 million shares, more than five times the average daily volume of 940,000. Market capitalization stood at approximately $20.21 billion intraday.

From a performance perspective, BNTX has now declined roughly 15.47% year-to-date and 25.96% over the past 12 months, starkly underperforming the MSCI World benchmark which is essentially flat YTD and up over 21% on a one-year basis.

With a trailing EPS of -$2.78, a price-to-book of just 1.19x, and a cash-rich balance sheet, some value-oriented investors may begin to take notice — though the leadership overhang is likely to keep sentiment cautious in the near term.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.